Name (Synonyms) | Correlation | |
---|---|---|
drug2327 | Quetiapine Wiki | 1.00 |
drug2698 | Standard of Care Wiki | 0.18 |
There is one clinical trial.
The primary purpose of this research is to determine whether Valproate alone, and in combination with Quetiapine, lowers confusion and agitation in persons with severe Corona Virus Disease (COVID)19 pneumonia during weaning from the breathing machine (ventilator). Though Valproate and Quetiapine are often given to persons with severe confusion with agitation, the purpose of this small research study is specifically for: a) persons infected with COVID 2019 on a ventilator whose agitation is not responding to the usual medications (like dexmedetomidine), and b) to reduce the time persons are treated with dexmedetomidine, which requires continuous close monitoring in an ICU.
Description: Richmond Agitation Sedation Scale (RASS) score ranges from +4 (combative) to 0 (alert & calm) to -5 (unarousable).
Measure: Change from baseline RASS score of +3 or greater Time: Baseline, Day 7Description: Total dose of dexmedetomidine administered will be reported from baseline RASS score of +3 or greater.
Measure: Total dose of dexmedetomidine administered Time: Day 7Description: Incidence of Treatment Emergent Adverse Events will include: QTc duration > 470 msecs. Increase in Liver Function Tests to a Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. Suicidality reported as having a score of moderate or high risk using the Columbia-Suicide Severity Rating Scale Screening (C-SSRS). C-SSRS is a calculated risk assessment tool that scores suicidality from no risk to high risk.
Measure: Incidence of Treatment Emergent Adverse Events Time: Day 7